<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00393744</url>
  </required_header>
  <id_info>
    <org_study_id>PRIST_L_01683</org_study_id>
    <secondary_id>EudraCT #: 2006-002127-16</secondary_id>
    <nct_id>NCT00393744</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Pristinamycin Versus Amoxicillin to Treat Tonsillitis Induced by Streptococcus in Children</brief_title>
  <acronym>PRI-angine</acronym>
  <official_title>A Phase III, Open, Randomised, Multicentre Study Comparing the Efficacy and Safety of Pristinamycin, at Dosages of 50 mg/kg/d in 2 Doses for Children, and 1g Twice Daily in Adults for 4 Days Versus Amoxicillin at a Dosage of 50 mg/kg/d in 2 Doses in Children and 1 g Twice Daily in Adults for 6 Days, Consumed Orally, in the Treatment of Tonsillitis Induced by Group-A Beta-Haemolytic Streptococcus in Patients Aged Between 6 and 25 Years.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to demonstrate the non-inferiority, at the assessment&#xD;
      visit (V3 (D10/D14)), in terms of bacteriological efficacy of pristinamycin (PRI)&#xD;
      administered for 4 days versus amoxicillin (AMX) administered for 6 days in the treatment of&#xD;
      tonsillitis caused by GAS, in subjects aged between 6 and 25 in the per protocol (PP) group.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>bacterial eradication</measure>
    <time_frame>at V3</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>during the study</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">395</enrollment>
  <condition>Tonsillitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pristinamycin</intervention_name>
    <description>50 mg/kg/d in 2 doses for children, and 1g twice daily in adults for 4 days</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amoxicillin</intervention_name>
    <description>50 mg/kg/d in 2 doses in children and 1 g twice daily in adults for 6 days</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  subjects of both sexes&#xD;
&#xD;
          -  aged between 6 and 25 years,&#xD;
&#xD;
          -  weight : ≥ 20kg&#xD;
&#xD;
          -  with suspected GAS-induced tonsillitis (erythema and/or exudate of the pharynx and/or&#xD;
             tonsils with oropharyngeal pain and/or odynophagia, fever ³ 38°C, appreciable&#xD;
             satellite adenopathy)&#xD;
&#xD;
          -  confirmation by positive RDT&#xD;
&#xD;
          -  provision of throat swabs for culture&#xD;
&#xD;
          -  ability to swallow tablets&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Related to the study disease:&#xD;
&#xD;
               -  suspected viral infection (concomitant dysphonia, cough, conjunctivitis,&#xD;
                  rhinitis)&#xD;
&#xD;
               -  adenophlegmon, peritonsillar abscesses.&#xD;
&#xD;
          -  Related to the study treatment:&#xD;
&#xD;
               -  known or suspected allergy to beta-lactamines (penicillin, cephalosporin)&#xD;
&#xD;
               -  suspected infectious mononucleosis (increased risk of skin disorders)&#xD;
&#xD;
               -  phenylketonuria (due to the presence of aspartame)&#xD;
&#xD;
               -  congenital galactosaemia, glucose/galactose malabsorption syndrome, lactase&#xD;
                  deficiency (due to the presence of lactose, in powder or suspension form)&#xD;
&#xD;
               -  allergy to pristinamycin and/or virginiamycin&#xD;
&#xD;
               -  history of pustular rash with pristinamycin&#xD;
&#xD;
               -  hypersensitivity or gluten intolerant (due to the presence of wheat starch)&#xD;
&#xD;
               -  ongoing treatment with cyclosporine, methotrexate, colchicine, allopurinol,&#xD;
                  tacrolimus or oral anticoagulants.&#xD;
&#xD;
          -  Related to previous treatment:&#xD;
&#xD;
               -  subjects receiving antibiotic therapy in the month prior to inclusion, except for&#xD;
                  azithromycin, for which the exclusion period is 3 months.&#xD;
&#xD;
               -  subjects on short-term corticosteroids. Subjects on long-term corticosteroids&#xD;
                  initiated before the start of the study and taken at a controlled dosage may be&#xD;
                  included.&#xD;
&#xD;
          -  Related to subjects:&#xD;
&#xD;
               -  breast-feeding women&#xD;
&#xD;
               -  women either pregnant or attempting to conceive&#xD;
&#xD;
               -  subjects likely, during the course of the study to receive treatments prohibited&#xD;
                  by the protocol&#xD;
&#xD;
               -  treatment with other investigational drugs in the 4 weeks prior to inclusion in&#xD;
                  the study&#xD;
&#xD;
               -  immunodepression, clinically significant endocrine disease, cardiovascular&#xD;
                  disease, neurological disease, or any other marked diseases resulting in&#xD;
                  complications in performance of the study or interpretation of the study data&#xD;
&#xD;
               -  known hepatic impairment&#xD;
&#xD;
               -  known renal impairment (creatinine clearance &lt; 30 ml/minute)&#xD;
&#xD;
               -  cancer, blood dyscrasias&#xD;
&#xD;
               -  previous history of drug or alcohol abuse.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie SEBILLE, Dr</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>October 27, 2006</study_first_submitted>
  <study_first_submitted_qc>October 27, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 29, 2006</study_first_posted>
  <last_update_submitted>March 16, 2009</last_update_submitted>
  <last_update_submitted_qc>March 16, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 17, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tonsillitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Pristinamycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

